Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Increase in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 56,900 shares, a growth of 151.8% from the November 15th total of 22,600 shares. Based on an average trading volume of 36,300 shares, the short-interest ratio is presently 1.6 days. Currently, 0.5% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a report on Thursday. They set a “sell” rating on the stock.

Akari Therapeutics Price Performance

AKTX stock traded up $0.05 during mid-day trading on Friday, reaching $1.00. The company had a trading volume of 63,952 shares, compared to its average volume of 23,546. The firm has a 50 day moving average of $2.01 and a 200 day moving average of $2.81. Akari Therapeutics has a 12 month low of $0.90 and a 12 month high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.